Premium
FCGR 3B copy number loss rather than gain is a risk factor for systemic lupus erythematous and lupus nephritis: a meta‐analysis
Author(s) -
Yuan Jin,
Zhao Dongbao,
Wu Lijun,
Xu Xia,
Pang Yafei,
Zhang Jun,
Ma Yanyun,
Liu Jie,
Wang Jiucun
Publication year - 2015
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12342
Subject(s) - lupus nephritis , medicine , systemic lupus erythematosus , meta analysis , immunology , dermatology , disease
Aim Some studies have been performed to elucidate the association between Fc gamma receptor 3B ( FCGR 3B ) copy number ( CN ) and the risk of systemic lupus erythematosus ( SLE ) and/or lupus nephritis ( LN ), yet the results remain conflicting. Therefore, we have undertaken a systematic review of all the studies published and carried out a meta‐analysis to obtain a better understanding of the role of FCGR 3B CN in the susceptibility of SLE and LN . Method A computerized literature search was conducted in databases of PubMed, ISI Web of Knowledge for all studies investigating the association between FCGR 3B CN and SLE and/or LN , published up to May 2013. Results A total of six articles meeting all of the criteria were included in this study. There were five comparisons of SLE between 2490 patients and 4286 controls, and four comparisons of LN between 689 patients and 1924 controls. Our results showed that individuals with FCGR 3B CN gain did not suffer an increased risk of SLE or LN as compared to the normal genotype in the total analysis ( SLE : OR = 1.07, 95% CI = 0.79–1.45, P = 0.65; LN : OR = 0.83, 95% CI = 0.47–1.46, P = 0.52). However, individuals with FCGR 3B CN loss exhibited an increased risk of SLE or LN ( SLE : OR = 1.77, 95% CI = 1.51–2.06, P < 0.00001; LN : OR = 2.02, 95% CI = 1.59–2.57, P < 0.00001). Conclusion Our meta‐analysis indicated that FCGR 3B CN loss rather than CN gain was associated with susceptibility to SLE and LN .